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Introduction
Adenosine is a nucleoside, which activates a family of Gcoupled protein receptors, named adenosine receptor (AR), type 1 (A 1 ), 2A (A 2A ), 2B (A 2B ), and 3 (A 3 ), and can control expression of pro-angiogenic factors such as vascular endothelial growth factor (VEGF) [1] [2] [3] [4] [5] [6] . However, depending on the tissue or cell approach, A 2A and A 2B may play a dominant role in regulating pro-angiogenic processes [2, 4, 7, 8] . In particular, A 2A can mediate cell proliferation/migration and synthesis of pro-angiogenic factors in many human, porcine, and rat endothelial cells [1] . These and other observations [9] have linked adenosine and adenosine receptor with upregulation of angiogenesis processes.
On the other hand, pre-eclampsia, a maternal syndrome characterized by placental hypoxia, new onset of hypertension, and proteinuria, is associated with high adenosine levels in umbilical blood [10, 11] . Causes and consequences of this elevated adenosine extracellular levels are not well established. However, other [12] and we [13] have suggested that it may impact placental angiogenesis. In particular, Iriyama et al. [12] described a mice model of increased placental adenosine levels, which results in a pre-eclampsia-like syndrome. This animal model also presented elevation of soluble vascular endothelial growth factor receptor type 1 (sFLT-1) and reduced expression of endothelial markers in the placenta, suggesting that high adenosine levels may instead have detrimental effect on placental angiogenesis.
Contrary to this last view, stimulation of A 2A triggers nitric oxide (NO) synthesis, enhancing VEGF protein expression in human umbilical vein endothelial cells (HUVECs) from normal pregnancy [14] . Also, the inhibitor of NO synthase, N ω -nitro-L-arginine methyl ester hydrochloride (L-NAME), blocked A 2A -mediated upregulation of VEGF expression (protein and messenger RNA (mRNA)) suggesting that NO is down stream of A 2A -mediated VEGF in HUVEC from normal pregnancies. Nevertheless, pharmacological studies suggest that HUVECs derived from pre-eclampsia diagnosed after 34 weeks of gestation (late-onset pre-eclampsia (LOPE)) present a basal upregulation of A 2A -NO-VEGF signaling pathway.
Changes in vessel formation within the human preeclamptic placenta are controversial [15] [16] [17] [18] [19] [20] [21] . In particular in LOPE, stereological studies evidenced no changes [22] , while estimation of endothelial markers such as CD31 [18] or CD34 [17] denoted elevated placental angiogenesis compared to normotensive controls. Despite this discrepancy, previous in vitro studies also supported a pro-angiogenic behavior of HUVEC isolated from LOPE [14] . Then, it is feasible that increased vessel formation in placentas from LOPE would facilitate oxygen/nutrient transfer between mother and fetus [23] as a compensatory mechanism looking for adequate fetus growth. Knowledge about A 2A -NO-VEGF signaling pathway in this potential placental compensatory mechanism is limited.
Taken all these evidences into account, we aim to investigate whether A 2A -NO-mediated regulation of VEGF expression is impaired in feto-placental endothelial cells from LOPE pregnancies.
Methods Patients
Pregnant women who attended to the Obstetric and Gynecology Department of the Herminda Martin Clinical Hospital (HCHM), Chillan, Chile, for their delivery were included as described previously by our group [14] . Exclusion criteria included chronic hypertension, altered renal function, diabetes, chronic disease, twin pregnancies, recurrent miscarriages, and abruption placenta. Women were classified into normal pregnancy (maternal blood pressure < 140/90 mmHg, absence of proteinuria, and no medical complications) and late-onset pre-eclampsia (new onset hypertension defined as blood pressure ≥ 140/90 mmHg with at least two measurements 6 h apart and proteinuria >300 mg/24 h) developed after 34 weeks of gestation. Each woman signed a written informed consent in the previous enrolment. The Ethical Committee from the Universidad del Bío-Bío approved this cohort study (Fondecyt 1140586).
Placentas and their umbilical cords were collected aseptically after birth by qualified Gynecology Service HCHM staff and then were processed in our laboratory at Department of Basic Sciences at the University of Bio Bio.
Use of agonists/antagonists of adenosine receptors
Specific agonist for A 2A receptor, 2-(p-(2-carbonyl-ethyl)-feniletilamino)-50-N-ethylcarboxamidoadenosine) (CGS-21680; Sigma-Aldrich, MO, USA), at a maximum concentration of 10 −8 M was used [24] . Also, we used the selective A 2A Antibodies used were anti-A 2A (Merck Millipore, Darmstadt, Germany) and anti-β-actin (Sigma-Aldrich, MO, USA).
Endothelial cell cultures
In order to test whether adenosine-mediated VEGF expression is a broadly effect on endothelial cells, we used two primary cultures of endothelial cells (macrovascular and microvascular) and one cell line of HUVEC (see supplementary information). Briefly, human placental microvascular endothelial cells (hPMECs) [28] and HUVEC [14] were isolated from normal and pre-eclamptic placentas as previously described by our group. Experiments were performed at standard culture condition (37°C, 5 % CO 2 ) without control of oxygen tension. Nevertheless, in parallel experiments, the cell line of HUVECs was also incubated at 2 % oxygen (i.e., hypoxia) (see supplementary information).
Small interference RNA for A 2A receptor
Human umbilical vein endothelial cells from normal and preeclamptic pregnancies were placed in culture dish (60 mm) until 60 % confluence. Cell were transfected with small interference RNA for A 2A receptor (small interference RNA (siRNA)-A 2A , 0.1 μg/μl) by using transfection medium, as recommended by manufacturers (Santa Cruz Biotechnology, USA). After that, the medium was shifted by M199 containing 5 mM D-glucose, 20 % new born calf serum (NBCS), 20 % fetal calf serum (FCS), 3.2 mM L-glutamine, and 100 U/ml penicillin-streptomycin (primary culture medium (PCM)), and cells were allowed to grow for 48 h under standard conditions (37°C, 5 % CO 2 ). Then, cells were starving and exposed to agonists as described above.
Cell proliferation
Endothelial cells taken from normal and pre-eclamptic pregnancies (hPMEC or HUVEC) were cultured in conditions described above and used for cell proliferation analysis. Briefly, cells (7 × 10 3 cell/ml) were seeded in 96-well plate and maintained in growth in standard conditions (PCM, 37°C, 5 % CO 2 ) for 12 h. After serum deprivation, cells were then incubated with 5-bromo-2-deoxyuridine (BrdU) in the presence of adenosine deaminase (ADA, 0.1 U/ml) and CGS-21680 (10 −8 M) or SNAP (10 −9 M) during additional 24 h. Cells were fixed, and ELISA for detection of BrdU was performed according to the manufacturer's instructions (Roche Diagnostics, IN, USA).
In vitro angiogenesis
In vitro angiogenesis assay on matrigel was performed by using primary culture of HUVEC from normal and preeclamptic pregnancies exposed or not to siRNA for A 2A receptor (Santa Cruz Biotechnology, CA, USA). Briefly, HUVECs (4 × 10 4 cell) previously transfected or not to siRNA for A 2A were cultured in 96-well plates coated with 40 μl of Matrigel basement membrane matrix (Corning, MA, USA). Under these conditions, cells were stimulated with CGS-21680 (10 −8 M, 6 h) or SNAP (10 −9 M, 6 h) and incubated under standard conditions (37°C and 5 % CO 2 ). Tube length was quantified by using the BAnalyzer Angiogenesisp lugin from the ImageJ (NIH, USA) software.
RNA extraction and reverse transcription
Total RNA was isolated by using Trizol (Thermo Fisher Scientific, MA, USA). RNA was quantified by spectrophotometry (A 260 nm), and its integrity was assessed by the A 260/280 nm ratio and directly observed in an agarose gel (2 %). Aliquots of 1 μg of total RNA were used in the reverse transcription reaction by using oligo dT, random primers, and the enzyme Moloney Murine Leukemia Virus-reverse transcriptase (MMLV-RT, Promega, USA) in a cycle of reverse transcription at 37°C as described elsewhere [14] . 
Results
Patients
Eighteen pregnant women were included (normotensive, n = 10; pre-eclampsia, n = 8). Clinical characteristics are included in Table 1 . According to inclusion criteria, preeclamptic women had higher systolic and diastolic blood pressure than women with normal pregnancy (p < 0.002, in both cases). Pre-eclamptic women had proteinuria (460.0 ± 60.0 mg/ day), while it was absent in normotensive women. No other statistically significant differences were observed in maternal, newborn, or placental parameters.
Characterization of the A 2A -NO pathway in feto-placental endothelium Figure 1 shows functional characterization of A 2A -NO pathway in HUVEC and hPMEC. Thus, in HUVEC, stimulation of A 2A receptor by CGS-21680 increases proliferation in normal pregnancies (Fig. 1a) (Fig. 1b) . In parallel experiments, cells were exposed to SNAP (Fig. 1c) . logEC 50 Also, CGS-21680 increases cell proliferation in hPMEC isolated from normal pregnancies in a dose response manner (logEC 50 of 10 −8.7 M; 95 % CI 10 −9.3 to 10 −8.2 M) (Fig. 1d ).
In addition, CGS-21680 increased protein levels of VEGF in hPMEC from normal (∼1.5-fold) and pre-eclamptic pregnancies (∼1.2 times) (Fig. 1e) . This increase in VEGF protein levels was blocked by the A 2A antagonist, ZM-241385 (10 −5 M), or by the inhibitor of NO synthase, L-NAME, in cells from normal and pre-eclamptic pregnancies. Interestingly, incubation with ZM-241385 or L-NAME alone reduced the abundance of VEGF in hPMEC from normal pregnancies (40 and 80 %, respectively). Meanwhile, in preeclampsia, this reduction was less evident, in particular with L-NAME in which it reached only 15 % with respect to basal conditions without stimulation.
A 2A is required for angiogenesis in vitro
The expression and function of A 2A were diminished by siRNA without affecting cell viability (see Fig. 2 ). Transfected cells with siRNA for A 2A exhibited a lower increase in the cAMP intracellular levels after stimulation with CGS-21680 than non-transfected cells (7.8-fold vs 31.5-fold, respectively) (Fig. 2d) . Similarly, nitrite levels in the culture medium were increased (2.6-fold) in the presence of CGS-21680, which was reversed when the cells were exposed to siRNA for A 2A (Fig. 2e) . Also, CGS-21680 increased in vitro angiogenesis in nontransfected cells, while cells exposed to siRNA for A 2A showed a reduction in this ability either in the absence or presence of CGS-21680 (Fig. 3) . It is notable that SNAP partially reverted the reduced in vitro angiogenesis in cells exposed to siRNA for A 2A (Fig. 3) . (Fig. 4) . In turn, the stimulatory effect of CGS-21680 was absent in cells transfected with siRNA for A 2A . However co-incubation of SNAP and CGS-21680 partially recovered the inhibitory effect of siRNA for A 2A in HUVEC from normal pregnancies. Similarly, in cells from pre-eclampsia, the presence of siRNA for A 2A blocked the stimulatory effect of CGS-21680 on cell proliferation. But contrary to what was observed in cells from normal pregnancies, co-incubation of CGS-21680 and SNAP, either in the presence or absence of siRNA for A 2A , was not be able to modify significantly cell proliferation (Fig. 4) .
Loss of A 2A affects mRNA levels of VEGF
In HUVEC from normal pregnancies, CGS-21680 increased (∼1.5-fold) mRNA level of VEGF, which was avoided in cells transfected with siRNA for A 2A (Fig. 5) . Similar to what was observed in cell proliferation, co-incubation of SNAP and CGS-21680 partially recovered the inhibitory effect of siRNA for A 2A on VEGF mRNA levels in HUVEC from normal pregnancies. Contrarily, in HUVEC from pre-eclampsia, differences did not reach statistical significance.
Discussion
Results confirm the functional presence of A 2A -NO-VEGF pathway in feto-placental endothelial cells in normal pregnancies. Also, we found that bioavailability of NO generated by activation of A 2A in cells from pre-eclampsia might be altered, thwarting its regulatory function on VEGF expression and thereby its pro-angiogenic capacity.
We have included a group of pre-eclamptic patients whose disease was present after 34 weeks of gestation, defined as LOPE. Rationality for using this pathology was because we have previously described elevated basal (i.e., without stimulation) activity of A 2A -NO-VEGF signaling pathway in HUVEC derived from this disease [14] . Since LOPE is associated with less maternal and fetal complication than early onset pre-eclampsia (EOPE) [29, 30] , it is feasible that elevation of A 2A -NO-VEGF observed in fetal endothelium derived from LOPE might constitute a compensatory pro-angiogenic mechanism for normal fetal development. Compatible with this last hypothesis, fetal and placental weights were similar in LOPE compared to normal pregnancy, but these parameters were reduced in EOPE [14] .
Nevertheless, placenta hypoxia can be present in LOPE as suggested for increased placental expression of hypoxia inducible factor [31] . Then, even increased angiogenesis observed in LOPE may be insufficient to overcome both the reduced oxygen delivery that is due to the infarcted placenta and the reduced oxygen delivery that would be predicted with failed remodeling of the maternal spiral arteries supplying the intervillous space [32] . More work is needed to better assess the role of hypoxia in the increased placental angiogenesis present in LOPE.
Regarding feto-placental endothelial cells used in this study, it has been shown that cells from microcirculation (i.e., hPMEC) are more reactive to pro-angiogenic signals than macrovascular endothelium (i.e., HUVEC) [2, 33, 34] . Despite that, hPMEC and HUVECs have similar response to CGS-21680 when cell proliferation was analyzed (logEC 50 10 −8.7 M vs logEC 50 10 −9.6 M, respectively). Similar to what was observed in HUVEC [14] , CGS-21680 also increased VEGF protein levels in hPMEC, which, in turn, was reverted by the selective antagonist ZM-241385 or by the NOS inhibitor (L-NAME) in cells from either normal or pre-eclamptic pregnancies. Therefore, A 2A -NO-VEGF pathway seems to be a common pathway present along the placental circulation. Elevated circulating levels of adenosine in feto-placental circulation have been described in pre-eclamptic pregnancies [10, 11, 28, 35] . However, causes and consequences of this elevation are not well understood. Although, high placental adenosine levels were associated with either reduction in placental angiogenesis [12] or pro-angiogenic behavior in HUVEC [14] .
How adenosine may control placental angiogenesis is not entirely known. However, it has been described that adenosine A 2A (and A 2B ) receptors may increase endothelial proliferation/migration and in vitro angiogenesis capacity, as well as induce vasodilatation, increase the synthesis of proangiogenic factors (i.e., VEGF), or decrease expression of antiangiogenic factors such as sFLT-1 [see details in 1]. In particular, other [2, 4, 6] and we [14, 36] have previously showed that stimulation of A 2A receptor increased the expression of VEGF in endothelial cells, as confirmed in the current work.
For instance, in HUVEC cell line exposed to normoxia (21 % oxygen), situation in which A 2A exceeds to A 2B expression, the non-selective adenosine receptor agonist, Nethylcarboxamidoadenosine (NECA), increases (1.5 times) the expression of VEGF. But, when those cells were incubated in hypoxia (4.6 % oxygen, 1 or 3 h), there was a shift in the expression of A 2B over A 2A , associated with a significant increase in the expression and release of VEGF (eight times) [4] . Although we have not investigated expression of A 2B in this manuscript, previously, we have described high expression of A 2B in HUVEC from LOPE [36] . But contrary to what was found in hypoxia [4] , in HUVEC from pre-eclampsia, we did not find an increase in the VEGF protein levels after stimulation with NECA. Also, we found that both repression and overexpression of A 2A lead to reduction in VEGF mRNA levels in normoxic (21 % oxygen) conditions without significant changes in hypoxia (2 % oxygen, overnight) in a HUVEC cell line (see supplementary information). Then, future studies should block both A 2A and A 2B receptors in order to better characterize its participation for controlling VEGF expression in fetal endothelium from pre-eclampsia. Also, potential cross talk between A 2A and VEGF needs to be clarified.
Intracellular pathway involved in A 2 -mediated VEGF expression is not completely elucidated; however, we have found participation of NO in this process [14, 36] . Despite the A 2A -NO-VEGF pathway is present in pre-eclamptic pregnancies, participation of NO seems to be associated with gestational age of pre-eclampsia onset. Thus, while LOPE is characterized by elevation of A 2A -mediated NO-VEGF signaling, in EOPE (diagnosed <34 weeks of gestation), this particular Fig. 6 A 2A and NO signaling pathway regulate the expression of VEGF in normal and late-onset pre-eclampsia. In human feto-placental endothelium from normal pregnancy, activation of A 2A adenosine receptor triggers an intracellular pathway involved increased generation of cAMP, activation (serine 1175 phosphorylation) of nitric oxide synthase (eNOS), and generation of nitric oxide (NO) from L-arginine. Nitric oxide increases mRNA levels of VEGF via unknown (?) mechanism(s), which may include protein nitration. This A 2A -NO-VEGF pathway can lead to a pro-angiogenic behavior of feto-placental endothelium, since it can stimulate cell proliferation/migration and tube formation. In LOPE, this A 2A -mediated intracellular pathway is elevated (⇪), in particular eNOS activation, NO synthesis, and VEGF expression. Upregulation of A 2A -NO-VEGF pathway observed in LOPE may constitute a compensatory mechanism to hypoxia in the placenta pathway is decreased [14] . These results partially agree with those presented by Salsoso and colleagues [37] , since these authors found reduced expression of A 2A receptor in HUVEC isolated from LOPE, associated with elevation in the Larginine transport, the substrate for NO synthesis.
Also, results presented in this manuscript suggest that contrary to what was observed in cells from normal pregnancy, in those from LOPE, NO donor did not recover the reduction in mRNA levels of VEGF or cell proliferation induced by siRNA for A 2A . Mechanisms for this effect were not addressed in this manuscript; however, at least two possibilities can be noted. First, HUVEC from LOPE exhibited elevated nitrite levels in the culture medium, which was not further elevated in the presence of CGS-21680 [14] . Then, additional NO given by SNAP might not be useful since cells would be on saturated conditions. Second, high oxidative stress is well described in HUVEC from pre-eclampsia [see details in 38]; then, NO bioavailability would be impaired. Additional studies are required to fully understand this phenomenon.
In conclusion, we demonstrated that A 2A -NO-VEGF pathway controls VEGF expression and cell proliferation in HUVEC and hPMEC (Fig. 6 ). In LOPE, basal elevation of A 2A -NO-VEGF impaired cell response to NO donor, SNAP. We believe that the results may contribute in the understanding of adaptive processes in the fetal-placental circulation pregnancy with pre-eclampsia.
